Research programme: breast and ovarian cancer vaccine - IDM Pharma

Drug Profile

Research programme: breast and ovarian cancer vaccine - IDM Pharma

Alternative Names: Breast and ovarian cancer vaccines research programme - Epimmune

Latest Information Update: 05 Sep 2007

Price : $50

At a glance

  • Originator IDM Pharma; University of Washington
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Breast cancer; Ovarian cancer

Most Recent Events

  • 05 Sep 2007 Discontinued - Preclinical for Ovarian cancer in USA (unspecified route)
  • 05 Sep 2007 Discontinued - Preclinical for Breast cancer in USA (unspecified route)
  • 18 Aug 2005 IDM S.A. has merged with Epimmune to form IDM Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top